Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877840 | 0.77 | CA1 (0.41) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL13624095 | 0.76 | CA1 (0.39) | CA1CA2ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL21718943 | 0.76 | CA1 (0.39) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL22949457 | 0.76 | CA1 (0.53) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL21718904 | 0.74 | CA1 (0.38) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL21718945 | 0.74 | TAAR1 (0.40) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL21718833 | 0.71 | CA1 (0.36) | CA1CA2ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL19618080 | 0.64 | ELANE (0.35) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL24656018 | 0.64 | CA1 (0.48) | CA1CA2ALDH1A1CCR1CCR5 | |
| SCHEMBL24922437 | 0.64 | CA1 (0.48) | CA1CA2ALDH1A1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | CA1 4337/4885CA2 3011/4885ALDH1A1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.